我要投票 博奥生物在基因检测行业中的票数:162
· 外 推 电 报 ·
2025-04-04 03:15:17 星期五

【博奥生物是哪个国家的品牌?】

博奥生物是什么牌子?「博奥生物」是 博奥生物集团有限公司 旗下著名品牌。该品牌发源于北京市,由创始人程总在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力博奥生物品牌出海!通过在本页面挂载博奥生物品牌的产品链接和联系邮箱,可以提高博奥生物产品曝光!跨境电商爆单神器,目前只要100元/年哦~

成立于2000年,清华控股旗下,生命科学研究和健康产业的企业,打造集健康产品/健康管理和医疗康复于一体的大健康产业版块。

博奥生物集团有限公司于2000年9月30日在国务院、发改委、科技部、教育部、卫生部和北京市领导大力支持下,以清华大学为依托、联合华中科技大学、中国医学科学院、军事医学科学院注册成立,是生命科学研究和健康产业的国有创新型高科技企业。公司总部位于北京,现有员工2000多人,研发、生产、运营和服务基地超过10万平方米。

公司以生物芯片为核心技术平台,拥有研发、生产、销售以及全国第三方独立医学检验所服务为一体的大医学完整产业链,并响应国家关于“预防为主”的健康方针,将现代医学与中国传统医学紧密结合,打造出集健康产品、健康管理和医疗康复于一体的大健康产业版块。迄今,博奥生物在国内已经形成了北京、上海、重庆、成都等大型产业化基地,并形成了以北京博奥晶典生物技术有限公司为核心的产业化平台。

成立18年来,博奥生物依托清华大学和生物芯片北京国家工程研究中心雄厚的研发实力,已成功开发出生物芯片及相关试剂耗材、仪器设备、软件数据库、生命科学服务、临床检验服务、健康管理等系列数十项具有自主知识产权的产品和服务。公司先后获得德国TÜV莱茵公司颁发的ISO9001、ISO13485、ISO14000、ISO18000、ISO27000质量管理体系认证证书、美国组织相容性及遗传学协会(ASHI)认证证书和中国合格评定国家认可委员会实验室认证证书,其产品获得CFDA、CE 、GS、CB等国内外各类认证证书100余项。至今,博奥生物已在全球获得专利授权300余项,专利转化率较高。

因其优良的研发、生产、营销和服务团队,以及生物芯片技术平台和高标准的质保体系,博奥生物除与国内近百家三甲医院、高校、公安和司法机构建立了战略合作,还与罗氏应用科学、罗氏诊断、昂飞、热电等国际生命科学和医学诊断领域的公司建立了伙伴关系,产品及服务出口北美、欧洲、亚洲等三十多个国家和地区。其中,诊断用生物芯片及相关仪器产品已进入英国、德国、瑞典、意大利、西班牙、奥地利、瑞士、葡萄牙、芬兰、丹麦、日本、新加坡等国家的数百家医院。

英文翻译:Founded in 2000, Tsinghua holdings, a life science research and health industry enterprise, has created a large health industry section integrating health products / health management and medical rehabilitation. On September 30, 2000, with the support of the State Council, the national development and Reform Commission, the Ministry of science and technology, the Ministry of education, the Ministry of health and the leaders of Beijing Municipality, Bo'ao biological Group Co., Ltd. was established on the basis of Tsinghua University and registered with Huazhong University of science and technology, the Chinese Academy of Medical Sciences and the Academy of Military Medical Sciences. It is a state-owned innovative high-tech enterprise in life science research and health industry. The company is headquartered in Beijing, with more than 2000 employees and over 100000 square meters of R & D, production, operation and service bases. With biochip as the core technology platform, the company has a complete industrial chain of large-scale medicine integrating R & D, production, sales and the services of the national third-party independent medical laboratory. In response to the national health policy of "prevention first", the company closely combines modern medicine with traditional Chinese medicine to create a large-scale health industry integrating health products, health management and medical rehabilitation Industry forum. So far, Boao biology has formed large-scale industrialization bases in China, such as Beijing, Shanghai, Chongqing, Chengdu, and formed an industrialization platform with Beijing Boao Jingdian Biotechnology Co., Ltd. as the core. Since its establishment 18 years ago, relying on the strong R & D strength of Tsinghua University and biochip Beijing National Engineering Research Center, BOCOG bio has successfully developed dozens of products and services with independent intellectual property rights, including biochip and related reagent consumables, instruments and equipment, software database, life science services, clinical testing services, health management, etc. The company has successively obtained ISO9001, ISO13485, ISO14000, ISO18000, ISO27000 quality management system certification issued by Germany t Ü V Rhine company, Ashi certification and laboratory certification issued by China National Accreditation for conformity assessment. Its products have obtained more than 100 kinds of certification certificates at home and abroad, such as CFDA, CE, GS, CB, etc. So far, Bo'ao biology has obtained more than 300 patent authorizations in the world, with a high patent conversion rate. Due to its excellent R & D, production, marketing and service team, as well as the biochip technology platform and high standard quality assurance system, Boao biology has established strategic cooperation with nearly 100 top three hospitals, universities, public security and judicial institutions in China, as well as partnerships with companies in international life science and medical diagnosis fields such as Roche Applied Science, Roche diagnosis, onfe, thermoelectricity, etc Products and services are exported to more than 30 countries and regions in North America, Europe and Asia. Among them, diagnostic biochip and related instrument products have entered hundreds of hospitals in Britain, Germany, Sweden, Italy, Spain, Austria, Switzerland, Portugal, Finland, Denmark, Japan, Singapore and other countries.

本文链接: https://www.waitui.com/brand/126365a18.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

美国2月贸易逆差1227亿美元

美国商务部普查局4月3日发布数据,2月贸易逆差1227亿美元,预估为逆差1235亿美元,前值为逆差1314亿美元。(界面)

2小时前

美股大型科技股盘前普跌,苹果跌超7%

36氪获悉,美股大型科技股盘前普跌,截至发稿,苹果、亚马逊跌超7%,特斯拉、Arm、英伟达跌超6%,Meta跌超5%,谷歌跌超4%,微软、奈飞跌超3%。

2小时前

热门中概股美股盘前普跌,拼多多跌超6%

36氪获悉,热门中概股美股盘前普跌,截至发稿,拼多多跌超6%,京东跌超5%,百度、爱奇艺、阿里巴巴、B站、蔚来跌超3%,理想汽车跌超2%,网易、腾讯音乐、微博跌超1%。

2小时前

高测股份:控股股东张顼拟询价转让4.99%股份

36氪获悉,高测股份公告,公司控股股东张顼计划通过询价转让方式转让27,308,000股,占公司总股本的4.99%,转让原因为自身资金需求。出让方声明所持股份权属清晰,不存在限制或禁止转让情形,且不违反相关减持规定和承诺。本次询价转让的受让方需为具备相应定价能力和风险承受能力的机构投资者。本次询价转让的价格下限不低于发送认购邀请书之日(即2025年4月3日)前20个交易日高测股份股票交易均价的70%。

2小时前

欧盟成员国拟表决对美关税反制措施

欧盟高级官员4月3日表示,欧盟成员国计划9日投票表决针对美方25%钢铝关税的反制措施。欧盟委员会负责贸易和经济安全等事务的委员马罗什·谢夫乔维奇表示,不合理的关税最终只会适得其反,欧盟将以冷静、有步骤且团结一致的方式作出回应。(新华社)

2小时前

本页详细列出关于美康基因科学的品牌信息,含品牌所属公司介绍,美康基因科学所处行业的品牌地位及优势。
咨询